Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (2050)	11/15/2000 1:45:20 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 52153

I think the key to his statement was "reference" samples. One uses, when available, standards. On occasion, they are provided free of charge by NIH. I often used the immunoglobulin standards. They saved me a ton of time. Nobody in their correct mind provides the standards unless they're compensated to do such.... boring, non-innovative work. So.... that was actually the only part of the release that seemed justifiable..... I'll bet that reference standards are anxiously awaited. And the cash will be good for them, allowing some progress on "tangents". The remainder of the release was unrelated hype and advertisement for their instrument. Not commenting on quality as an investment. I'm interested, just not interested enough to do further research, given my lack of sophistication with this sort of instrument.